Skip to content
Defeating cancer with radiopharmaceutical medicines
San Diego, CA
Leader in targeted radiopharmaceuticals to improving cancer patient survival. Broad pipeline of innovative drugs against solid tumor targets.
RayzeBio Completes Phase 1b Enrollment in ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors
RayzeBio Announces Issuance of Two Patents for RYZ101 (225Ac-DOTATATE)
Building career-spanning relationships, from candidacy to organizational leadership, we provide access to the future of the Medtech and Pharma.
Work For Us